News | May 05, 2026
NIFTY Pharma remains resilient amid mixed market sentiment
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The company posted revenue of €1,267 million, up 6% on a constant currency basis
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Minimally invasive laser-based procedure restores blood flow in complex arterial blockage, enables next-day discharge and improved mobility
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
This development signals a cleanup of Anlon’s borrowing profile and closure of legacy debt facilities
To boost compostable packaging, resin innovation, and supply chain speed
Subscribe To Our Newsletter & Stay Updated
